These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 37277603)

  • 1. Glioblastoma heterogeneity at single cell resolution.
    Eisenbarth D; Wang YA
    Oncogene; 2023 Jun; 42(27):2155-2165. PubMed ID: 37277603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
    Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-cell RNA sequencing reveals tumor heterogeneity, microenvironment, and drug-resistance mechanisms of recurrent glioblastoma.
    Wu H; Guo C; Wang C; Xu J; Zheng S; Duan J; Li Y; Bai H; Xu Q; Ning F; Wang F; Yang Q
    Cancer Sci; 2023 Jun; 114(6):2609-2621. PubMed ID: 36853018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Zooming in" on Glioblastoma: Understanding Tumor Heterogeneity and its Clinical Implications in the Era of Single-Cell Ribonucleic Acid Sequencing.
    Khalafallah AM; Huq S; Jimenez AE; Serra R; Bettegowda C; Mukherjee D
    Neurosurgery; 2021 Feb; 88(3):477-486. PubMed ID: 32674143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma.
    Goenka A; Tiek D; Song X; Huang T; Hu B; Cheng SY
    Cells; 2021 Feb; 10(3):. PubMed ID: 33668200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma.
    Qazi MA; Vora P; Venugopal C; Sidhu SS; Moffat J; Swanton C; Singh SK
    Ann Oncol; 2017 Jul; 28(7):1448-1456. PubMed ID: 28407030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma.
    Shu C; Li Q
    Crit Rev Oncol Hematol; 2020 Jul; 151():102965. PubMed ID: 32442903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of glioblastoma (GBM) molecular classification methods.
    Lee E; Yong RL; Paddison P; Zhu J
    Semin Cancer Biol; 2018 Dec; 53():201-211. PubMed ID: 30031763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glioblastoma multiforme: novel therapeutic targets.
    Muir M; Gopakumar S; Traylor J; Lee S; Rao G
    Expert Opin Ther Targets; 2020 Jul; 24(7):605-614. PubMed ID: 32394767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment.
    Seyfrid M; Maich WT; Shaikh VM; Tatari N; Upreti D; Piyasena D; Subapanditha M; Savage N; McKenna D; Mikolajewicz N; Han H; Chokshi C; Kuhlmann L; Khoo A; Salim SK; Archibong-Bassey B; Gwynne W; Brown K; Murtaza N; Bakhshinyan D; Vora P; Venugopal C; Moffat J; Kislinger T; Singh S
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of immunotherapy resistance: lessons from glioblastoma.
    Jackson CM; Choi J; Lim M
    Nat Immunol; 2019 Sep; 20(9):1100-1109. PubMed ID: 31358997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid Cells in Glioblastoma Microenvironment.
    De Leo A; Ugolini A; Veglia F
    Cells; 2020 Dec; 10(1):. PubMed ID: 33374253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
    Umphlett M; Shea S; Tome-Garcia J; Zhang Y; Hormigo A; Fowkes M; Tsankova NM; Yong RL
    BMC Cancer; 2020 Jan; 20(1):47. PubMed ID: 31959133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Heterogeneity of Tumour-Associated Macrophages Contributes to the Recurrence and Outcomes of Glioblastoma Patients.
    Xuan Z; Fang L; Zhang G; Zhang X; Jiang J; Wang K; Huang P
    J Mol Neurosci; 2023 Jan; 73(1):1-14. PubMed ID: 36542317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging therapies for glioblastoma: current state and future directions.
    Rong L; Li N; Zhang Z
    J Exp Clin Cancer Res; 2022 Apr; 41(1):142. PubMed ID: 35428347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a unique tumor cell subset employing myeloid transcriptional circuits to create an immunomodulatory microenvironment in glioblastoma.
    Yang K; Shi Y; Luo M; Mao M; Zhang X; Chen C; Liu Y; He Z; Liu Q; Wang W; Luo C; Yin W; Wang C; Niu Q; Zeng H; Bian XW; Ping YF
    Oncoimmunology; 2022; 11(1):2030020. PubMed ID: 35096487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Microenvironment Characterization in Glioblastoma Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures.
    Zhang J; Xiao X; Zhang X; Hua W
    J Mol Neurosci; 2020 May; 70(5):738-750. PubMed ID: 32006162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Niches: Perspectives for Targeted Therapies in Glioblastoma.
    Srivastava R; Dodda M; Zou H; Li X; Hu B
    Antioxid Redox Signal; 2023 Nov; 39(13-15):904-922. PubMed ID: 37166370
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.